Evaluating Efficacy When Transitioning From A Current Disease Modifying Therapy 9Dmt) To Ublituximab (Enhance)
Posted Date: Jul 15, 2024
- Investigator: Lawrence Goldstick
- Specialties:
- Type of Study: Drug
This is a 48 week, Phase 3b multi-center study designed to investigate the efficacy and tolerability of transition from anti-CD20 monoclonal antibody or other DMT to ublituximab in participants with RMS. Additionally, the safety and tolerability of shorter infusion durations of ublituximab will be assess during the 450mg doses of ublituximab administered after W!D!.
Criteria:
Patients Age 18-65 Diagnosed With Rms That Were Previously Treated With Ocrelizumab, Rituximab, Ofatumumab That Have Met Washout Periods, That Are Wanting To Switch To Ublituximab. Must Have Edss Score Of 5.5 Or Less, Must Be Neurologically Stable For More Than 30 Days, Must Not Be Pregnant, Plan To Become Pregnant, Or Breastfeeding. Must Have A Good Response To Anti-Cd20 Therapy. Must Have Never Received Ublituximab, Alemtuzumab, Cyclophosphamide, Mitoxantrone, Cladribine, Or Daclizumab. Must Not Have Hepatitis B, Hepatitis C, Tb, History Of Pml.
Keywords:
Ublituximab, Rms, Anti-Cd20
For More Information:
Cecilia Quarles
937-535-5012
quarleys@ucmail.uc.edu